Viking Therapeutics announced plans to advance its oral obesity drug VK2735 into Phase 3 trials, expected to start in Q3 2026, resulting in a stock surge of over 14%. However, the company also reported a significant net loss of $157.7 million in Q4 2025, raising concerns about its financial health as it increases R&D spending to support drug development. The advancement of VK2735 highlights both the potential growth avenues for Viking Therapeutics and the fiscal challenges it currently faces.
“Viking Therapeutics plans to advance oral obesity drug to late-stage testing”
“Viking Therapeutics plans to advance oral obesity drug to late-stage testing.”
“Viking Therapeutics plans to advance oral obesity drug to late-stage testing.”
“Viking Therapeutics plans to advance oral obesity drug to late-stage testing https://t.co/6u9KxKCuUS https://t.co/6u9KxKCuUS”
“Viking Therapeutics (VKTX) closed up more than +7% after it said it plans to advance its oral obesity drug to Phase 3 in the third quarter of this year.”
“the rapid move into Phase III VANQUISH trials, early completion of VANQUISH‑1 enrollment... sharpen the near-term catalyst path around clinical data and regulatory dialogue.”
“Viking Therapeutics (VKTX) has put its clinical pipeline in the spotlight around its Q4 2025 earnings release, with fresh trial updates on obesity candidate VK2735 and an upcoming amylin agonist filing drawing investor attention.”
“However, the 90 day share price return of 22% and year to date share price return of 14% suggest momentum has cooled compared with the very large 5 year total shareholder return of just over 3x.”
“Our DCF model estimates a future cash flow value for Viking Therapeutics of $269.59 per share, compared with the last close of $30.49, highlighting a very wide valuation gap.”
“Viking trades at 4.9x book value, which is below its peer average of 5.4x but above the broader US Biotechs industry average of 2.7x.”
“Viking Therapeutics (VKTX) closed up more than +7% after it said it plans to advance its oral obesity drug to Phase 3 in the third quarter of this year.”
“Viking Therapeutics (VKTX) is up more than +10% after it said it plans to advance its oral obesity drug to Phase 3 in the third quarter of this year.”